ライフサイエンスコーパス: hypertensive patient

1 a high index of suspicion is needed in every hypertensive patient.

2 of uncomplicated hypertension in the elderly hypertensive patient.

3 that impaired corin activation activity in a hypertensive patient.

4 e intervals in 155 healthy volunteers and 40 hypertensive patients.

5 oversial in the treatment of acute stroke in hypertensive patients.

6 asures in diagnosing and adequately treating hypertensive patients.

7 e and aldosterone phenotype in a subgroup of hypertensive patients.

8 r patients with hypertension compared to non-hypertensive patients.

9 l benefits of renal denervation in resistant hypertensive patients.

10 olites are similar in healthy volunteers and hypertensive patients.

11 at may be triggered simultaneously in septic hypertensive patients.

12 r combination on the reduction of LV mass in hypertensive patients.

13 risk of cardiovascular events and death for hypertensive patients.

14 ssociated with ventricular hypertrophy in AA hypertensive patients.

15 ion, and genetic variations of RGS2 occur in hypertensive patients.

16 n and stroke among pharmacologically treated hypertensive patients.

17 ated rise in exercise blood pressure (BP) in hypertensive patients.

18 value in predicting cardiovascular events in hypertensive patients.

19 ve heart failure, similar to untreated human hypertensive patients.

20 of cardiovascular morbidity and mortality in hypertensive patients.

21 of bone morphogenetic protein receptor-2 in hypertensive patients.

22 pe 2 diabetes, reduce blood pressure (BP) in hypertensive patients.

23 of ECG LVH may predict improved prognosis in hypertensive patients.

24 ndothelium-dependent vasodilator function of hypertensive patients.

25 echanism for promotion of atherosclerosis in hypertensive patients.

26 ar properties and outcomes of lean and obese hypertensive patients.

27 hrine (200% vs. 500%, p < 0.05) in the obese hypertensive patients.

28 NE) (p < 0.01) in the lean but not the obese hypertensive patients.

29 and lean (BMI = 24.3 +/- 0.2 kg/m2, n = 66) hypertensive patients.

30 ary care providers and their black and white hypertensive patients.

31 the selection of drugs for the treatment of hypertensive patients.

32 he pathogenesis of cardiovascular disease in hypertensive patients.

33 lar cAMP, in 12 normotensive subjects and 12 hypertensive patients.

34 nts similar to those seen in untreated human hypertensive patients.

35 uretics would reduce the number of resistant hypertensive patients.

36 ity, and non-cardiovascular complications in hypertensive patients.

37 ciated increased atherosclerosis observed in hypertensive patients.

38 ventricular (LV) mass and wall thickness in hypertensive patients.

39 ay increase coronary heart disease events in hypertensive patients.

40 -sodium diets are frequently recommended for hypertensive patients.

41 c and renal artery repair in 133 consecutive hypertensive patients.

42 71%) non-hypertensive patients, and (30.29%) hypertensive patients.

43 oves peripheral insulin sensitivity in obese hypertensive patients.

44 wering strategies in older (age >/=65 years) hypertensive patients.

45 that ADAM17 was upregulated in the brain of hypertensive patients.

46 on and tested its potential to risk-stratify hypertensive patients.

47 ion with a prevalence of 5-10% in unreferred hypertensive patients.

48 nvasive central BP monitoring in elderly and hypertensive patients.

49 l be effective in reducing blood pressure in hypertensive patients.

50 tandard natural virgin olive oil in pre- and hypertensive patients.

51 ypertension treatment is beneficial for most hypertensive patients.

52 e effects of FVOO on endothelial function in hypertensive patients.

53 cardiovascular disease outcomes or death in hypertensive patients.

54 predict the onset of vascular dysfunction in hypertensive patients.

55 ng BT into beneficial dietary supplements in hypertensive patients.

56 age, smoking, kidney disease and diabetes in hypertensive patients.

57 (mass/end-diastolic volume [M/EDV](2/3)) in hypertensive patients.

58 s can decrease time to BP target among their hypertensive patients.

59 duction in the time to BP target among their hypertensive patients.

60 c sympathetic baroreflex function in elderly hypertensive patients.

61 mation for the clinical management of ocular hypertensive patients.

62 A total of 9193 hypertensive patients (1195 with diabetes) in the Losart

63 Among hypertensive patients, 22% with LVH had an abnormally lo

64 Endothelin was higher in hypertensive patients (4.6+/-0.2 fmol/mL) than in 20 con

65 t reliability of LV mass measurements in 183 hypertensive patients (68% men, 65 +/- 9 years) enrolled

66 and fractionated catecholamines, and, in the hypertensive patient, a serum potassium level and plasma

67 In hypertensive patients, a combined ET(A/B) blockade resul

68 smography in 37 normotensive patients and 27 hypertensive patients according to race.

69 ndomized, clinical trial in 33,357 high-risk hypertensive patients aged > or =55 years.

70 uretic-based regimens versus placebo in 4396 hypertensive patients aged 65-74 years.

71 Of 19342 hypertensive patients (aged 40-79 years with at least th

72 ess than 140/less than 90 mmHg in 50% of all hypertensive patients, an increase from 27% in 1988-1994

73 ress were compared in 12 normal subjects, 12 hypertensive patients and 10 hypercholesterolemic patien

74 y of the RI was examined in 256 asymptomatic hypertensive patients and 10 patients with heart failure

75 A cohort of 582 881 hypertensive patients and 260 924 normotensive individua

76 METHODS AND Cohort study included 92 hypertensive patients and 27 providers in 3 safety-net p

77 ceptors in pulmonary arteries from pulmonary hypertensive patients and control subjects, using in vit

78 nce of this ADAM17-mediated ACE2 shedding in hypertensive patients and further identify the cell type

79 PAMM lesions were found in 24 of 27 (88.9%) hypertensive patients and in 4 of 24 (16.7%) healthy ind

80 +)/H(+) exchanger, has increased activity in hypertensive patients and in animal models of hypertensi

81 ss, reflecting subclinical oedema, occurs in hypertensive patients and in association with aging.

82 enzyme (ACE) inhibitors and beta-blockers in hypertensive patients and in patients with heart failure

83 independent predictor of clinical events in hypertensive patients and in the general population.

84 that RI provides an approach for stratifying hypertensive patients and is suitable for testing in oth

85 (-)-epicatechin reduces blood pressure in hypertensive patients and limits infarct size in animal

86 Chronic PAMM lesions are highly prevalent in hypertensive patients and may represent the earliest cha

87 l metabolites in the systemic circulation of hypertensive patients and rodent models of hypertension.

88 cies of the two variants were similar in the hypertensive patients and the control subjects.

89 an matched case-control studies, 1 nested in hypertensive patients and the other in patients with car

90 alanced data set of 24,434 with (69.71%) non-hypertensive patients, and (30.29%) hypertensive patient

91 en 1966 and end 2013 in cohorts with >/= 40% hypertensive patients, and exclusive of trials in acute

92 on was more frequent in older patients, men, hypertensive patients, and those presenting with ST-segm

93 frican American patients, Hispanic patients, hypertensive patients, and those with hypertrophy.

94 have increased risk compared with unselected hypertensive patients, and use of hospitalization for he

95 ingle nucleotide polymorphisms identified in hypertensive patients are located in the human RGS2 prom

96 patients, cardiovascular properties in lean hypertensive patients are more dependent on catecholamin

97 Hypertensive patients are often given a calcium antagoni

98 particularly beneficial in some subgroups of hypertensive patients, as those who are at highest cardi

99 bleeds which predicts cerebral hemorrhage in hypertensive patients, as well as progression to hyperte

100 bidity and mortality more than amlodipine in hypertensive patients at high cardiovascular risk.

101 portance of prompt blood-pressure control in hypertensive patients at high cardiovascular risk.

102 ge randomized trials that randomly allocated hypertensive patients at high risk for cardiovascular di

103 Increased pulse pressure may help identify hypertensive patients at high risk for overt CHF who are

104 ECG strain identifies hypertensive patients at increased risk of developing CH

105 Development of new-onset AF identifies hypertensive patients at increased risk of SCD.

106 Among hypertensive patients, awareness, treatment, and control

107 t of proteinuria was highest in persistently hypertensive patients between years 1-3.

108 Among hypertensive patients, black patients were 2.5 to 2.9 an

109 In a fourth study, 6 hypertensive patients (blood pressure >160/100 mm Hg) re

110 th, but at 6 months, levels were elevated in hypertensive patients but not in normotensive patients (

111 sion significantly lowered blood pressure in hypertensive patients but not in normotensive subjects (

112 s contribute to vascular remodeling in obese hypertensive patients by activating protein kinase C (PK

113 Compared with obese hypertensive patients, cardiovascular properties in lean

114 In mildly to moderately hypertensive patients, carotid intima-media thickness an

115 Among examined cognitive variables, hypertensive patients committed significantly more perse

116 response to ACh was significantly blunted in hypertensive patients compared with controls (P<0.001),

117 in both mRNA and protein FGF1 expression in hypertensive patients compared with normotensive control

118 ased after transplant and was greater in the hypertensive patients compared with the normotensive pat

119 declined by 8%; use of antihypertensives by hypertensive patients decreased by 10%.

120 studies in both drug-naive and drug-treated hypertensive patients demonstrated a significant reducti

121 compared with less than 140 mmHg in diabetic hypertensive patients does not appear to decrease the de

122 reactive pulmonary vasculature in pulmonary hypertensive patients during acute vasodilator testing a

123 In hypertensive patients, endothelial microparticles indeed

124 morbidity and mortality have been reduced in hypertensive patients, even in those with hyperlipidemia

125 Compared with controls, hypertensive patients exhibited a decreased flow-mediate

126 140 image pairs from 100 glaucomatous/ocular hypertensive patient eyes using a handheld stereo viewer

127 hypertension therapy, significant numbers of hypertensive patients fail to achieve recommended blood

128 In hypertensive patients, fenoldopam rapidly decreases bloo

129 ar dysfunction in approximately one fifth of hypertensive patients for whom concomitant LVH was found

130 We selected 1447 hypertensive patients from a 3-year benazepril postmarke

131 ficantly reduced after vitamin C infusion in hypertensive patients (from 53.3 +/- 12.2 to 47.4 +/- 11

132 Hypertensive patients had elevated CHGA coupled with red

133 an normotensive subjects, the lean and obese hypertensive patients had greater left ventricular mass

134 Hypertensive patients have been found to be associated w

135 ual variability in blood pressure in treated hypertensive patients have been ignored.

136 Hypertensive patients have both impaired endothelium-dep

137 Moreover, human hypertensive patients have demonstrated increased suscep

138 Although lean hypertensive patients have fewer metabolic abnormalities

139 Hypertensive patients have impaired endothelium-dependen

140 Approximately 5% of all hypertensive patients have renovascular hypertension, al

141 In 9 normal controls (NC), 11 hypertensive patients (HT), and 12 hypercholesterolemic

142 ug) as initial therapy in several subsets of hypertensive patients (i.e., those with diabetes and nep

143 content, we analyzed samples from 14 mildly hypertensive patients in a crossover study during a high

144 ntly reduce cardiovascular events in treated hypertensive patients in ASCOT did not influence central

145 ss (22%) in the obese than in the lean (55%) hypertensive patients in response to standing (p < 0.05)

146 baseline and after 1 year of therapy in 7409 hypertensive patients in the LIFE study (Losartan Interv

147 ly important in treated mildly to moderately hypertensive patients in whom treatment aims at avoiding

148 ulse pressure ratio) was reduced in the lean hypertensive patients, in whom it correlated (p = 0.033)

149 dent predictor of cardiovascular outcomes in hypertensive patients including myocardial infarction, f

150 Two hundred fifty-six overweight or obese hypertensive patients, including 54% black and Hispanic

151 e plays a role in endothelial dysfunction in hypertensive patients independent of insulin resistance.

152 rosis and to increased arterial stiffness in hypertensive patients, independent of age.

153 ith the risk of primary cardiac arrest among hypertensive patients, independent of conventional binar

154 In older hypertensive patients, intensive BP control (systolic BP

155 igate whether the endothelial dysfunction of hypertensive patients is related to a selective defect i

156 ing self-monitoring to no self-monitoring in hypertensive patients (June 2016).

157 DAM17-mediated ACE2 shedding in the brain of hypertensive patients, leading to a loss in compensatory

158 f late gadolinium enhancement, as well as of hypertensive patients LV wall thickness of >15 mm (P<0.0

159 erm safety, these data suggest that selected hypertensive patients may be accepted for living kidney

160 Heart failure (HF) developing in hypertensive patients may occur with preserved or reduce

161 In addition, within hypertensive patients (n = 469), patients using angioten

162 Interestingly, untreated hypertensive patients (n=20) had a cerebral blood flow s

163 Finally, using ELISA, we found that hypertensive patients (n=31) have higher plasma levels o

164 Most hypertensive patients need two or more drugs for blood-p

165 d whether diastolic function differs between hypertensive patients of African-Caribbean or white Euro

166 Diastolic function is significantly worse in hypertensive patients of African-Caribbean origin than i

167 in normotensive Afro-Caribbean people and in hypertensive patients of all ethnic origins.

168 We randomized 126 hypertensive patients on hemodialysis to a standardized

169 Treatment of hypertensive patients over age 80 with indapamide and an

170 significant increase in FBF from baseline in hypertensive patients (P<0.008) but not in controls (P=0

171 +/-1.4 s(-1) (95% CI, -0.8 to -2.6 s(-1)) in hypertensive patients (P=0.0003).

172 mic patients (p=0.03 vs. saline), but not in hypertensive patients (p=0.69 vs. saline).

173 In previous clinical trials in high-risk hypertensive patients, paradoxically higher cardiovascul

174 ave fewer metabolic abnormalities than obese hypertensive patients, paradoxically they appear to have

175 y be considered for primary AF prevention in hypertensive patients, previous studies have yielded con

176 In hypertensive patients, primary prevention of HF is stron

177 and sex-matched RA-normotensive (n = 13), RA-hypertensive patients (RA-HTN; n = 17), normotensive (NC

178 Thirteen pre- and stage-1 hypertensive patients received a single dose of 30 mL of

179 We aimed to assess the risk of cancer in hypertensive patients receiving ACE inhibitors or other

180 turnal arterial hypotension, particularly in hypertensive patients receiving oral hypertensive therap

181 Treating hypercholesterolemia in hypertensive patients reduces residual CHD risk >35%.

182 and resistance arteries in normotensive and hypertensive patients referred for cardiac catheterizati

183 sm but instead can be effective in resistant hypertensive patients regardless of aldosterone levels.

184 bled the risk for heart failure in high-risk hypertensive patients (relative risk, 2.04 [95% CI, 1.79

185 Despite progress, many hypertensive patients remain uncontrolled.

186 There is a marked variability in hypertensive patients' response to different antihyperte

187 icacy of antihypertensive agents in treating hypertensive patients, safety and efficacy of antihypert

188 A total of 346 uncontrolled hypertensive patients, separated according to daytime am

189 eased use of healthcare resources, resistant hypertensive patients should be identified early, and gr

190 lony-forming cells from idiopathic pulmonary hypertensive patients showed upregulation of CLIC4 expre

191 On the contrary, in 16 hypertensive patients, sodium nitroprusside in equidepre

192 ertension is a valuable approach to managing hypertensive patients suffering from acute ischemic stro

193 characterized cohort of untreated borderline hypertensive patients suggested that ARHGAP42 genotype h

194 was twofold greater (p < 0.05) in pulmonary hypertensive patients than in control subjects.

195 h urinary nitrate excretion was lower in the hypertensive patients than in the control group (mean 45

196 interventions provides multiple benefits to hypertensive patients that extend beyond a reduction in

197 Only a single study has been reported in hypertensive patients that links baseline sodium, measur

198 me (ACE) inhibitors reduce blood pressure in hypertensive patients, the clinical trial evidence in te

199 In high-cardiovascular-risk treated hypertensive patients, the incidence of cardiovascular e

200 In contrast, in hypertensive patients, the vasodilator effect of ET(A) r

201 ndothelium-dependent vasodilator function in hypertensive patients, thereby suggesting that an increa

202 To evaluate the heightened risks in lean hypertensive patients, this study compared metabolic, ne

203 de (HCTZ) in reducing blood pressure (BP) in hypertensive patients, though both are plagued with BP r

204 s issue further, we studied a large group of hypertensive patients to investigate the relation of cal

205 might explain an increased susceptibility of hypertensive patients to vascular damage over repeated e

206 f antihypertensive drugs, in untreated young hypertensive patients, to assess the response rate with

207 Hypertensive patients underwent multimodal cardiac asses

208 were measured in 2937 mildly and moderately hypertensive patients unmedicated for > or = 3-4 wk.

209 y of retinopathy was significantly higher in hypertensive patients versus those without hypertension

210 out hypertension, upregulation of chymase in hypertensive patients was much stronger than that seen i

211 Nerve anatomy in hypertensive patients was not considerably different com

212 However, HHcy's role in hypertensive patients was not studied.

213 n, which routinely hampers the management of hypertensive patients, was absent in knock-ins.

214 In hypertensive patients, we found that arteriosclerosis wa

215 Four of fourteen hypertensive patients were able to discontinue antihyper

216 Hypertensive patients were compared with nonhypertensive

217 eart Attack Trial (ALLHAT), 42 418 high-risk hypertensive patients were randomized to chlorthalidone,

218 ELT can be considered in glaucoma and ocular hypertensive patients whenever cataract surgery is perfo

219 and support in the control and detection of hypertensive patients, which is part of the critical fac

220 to reduce cardiovascular adrenergic drive in hypertensive patients, which suggests that oxidative str

221 ACE2 activity in the cerebrospinal fluid of hypertensive patients, which was correlated with systoli

222 Hypertensive patients who are healthy, functionally inde

223 revention of coronary heart disease (CHD) in hypertensive patients who are not conventionally deemed

224 pared with patients who did not develop CHF, hypertensive patients who developed CHF were older; were

225 We used a retrospective cohort study of hypertensive patients who had filled prescriptions for 1

226 Cases (n = 189) were hypertensive patients who had had a first cardiovascular

227 may decrease retinopathy progression in non-hypertensive patients who have type 1 diabetes with litt

228 use of amiloride plus hydrochlorothiazide in hypertensive patients who need treatment with a diuretic

229 We enrolled 16 hypertensive patients who responded to treatment with an

230 d random sample of pharmacologically treated hypertensive patients who were matched to MI cases by ag

231 n of Ang II (3 ng x kg(-1) x min(-1)) in 190 hypertensive patients who were on carefully controlled h

232 In one (1.1%) hypertensive patient, who developed bilateral branch ret

233 ith PegIFNalpha and ribavirin, especially in hypertensive patients, who may develop serious complicat

234 e main outcome measure was the percentage of hypertensive patients whose hypertension was controlled

235 hould be considered in the evaluation of the hypertensive patient with poor blood pressure control.

236 In hypertensive patients with a low plasma renin but normal

237 Twelve hypertensive patients with a mean ambulatory blood press

238 4 high-quality trials involving 10,857 older hypertensive patients with a mean follow-up of 3.1 years

239 ischemic events may occur more frequently in hypertensive patients with activated renin-angiotensin s

240 mage and accelerated kidney function loss in hypertensive patients with and without chronic kidney di

241 nance imaging to accurately quantify LVM, in hypertensive patients with and without LVH and in normal

242 In hypertensive patients with aorto-ostial atherosclerotic

243 s of renal artery stent revascularization in hypertensive patients with aorto-ostial atherosclerotic

244 in asymptomatic high-risk prehypertensive or hypertensive patients with blood pressure (BP) controlle

245 Factors leading to adverse outcomes in hypertensive patients with CAD are poorly understood.

246 dolapril STudy (INVEST) compared outcomes in hypertensive patients with CAD that were assigned random

247 In hypertensive patients with CAD who are >/=60 years of ag

248 In hypertensive patients with CAD, increased risk for adver

249 This is a post hoc analysis of hypertensive patients with CAD.

250 Twenty hypertensive patients with CFDI suggestive of RA FMD (mi

251 determine predictors for adverse outcomes in hypertensive patients with coronary artery disease (CAD)

252 rdial infarction [MI] or nonfatal stroke) in hypertensive patients with coronary artery disease (CAD)

253 Hypertensive patients with diabetes have less regression

254 cohort study, we analyzed treatment of 8127 hypertensive patients with diabetes mellitus treated by

255 ain the higher CV morbidity and mortality in hypertensive patients with diabetes, and the absence of

256 useful as a surrogate marker of outcomes in hypertensive patients with diabetes.

257 cular disease and to 44 age- and sex-matched hypertensive patients with diastolic dysfunction (hypert

258 glaucoma was six times more likely in ocular hypertensive patients with disc hemorrhages compared wit

259 grams were examined at study baseline in 886 hypertensive patients with ECG LVH by Cornell voltage-du

260 versus atenolol therapy was assessed in 9193 hypertensive patients with ECG LVH by Sokolow-Lyon volta

261 of SCD to new-onset AF was evaluated in 8831 hypertensive patients with electrocardiographic left ven

262 In these treated male hypertensive patients with good blood pressure control (

263 perties and therefore has a role in treating hypertensive patients with gout.

264 ive myocardial CCL is associated with HHF in hypertensive patients with HF.

265 rebral vessels were most frequently found in hypertensive patients with high and very high total card

266 Hypertensive patients with hyperaldosteronism or normal

267 Hypertensive patients with hypokalaemia, together with t

268 tan-based to atenolol-based therapy in 9,193 hypertensive patients with left ventricular hypertrophy

269 between the ADC value and systolic strain in hypertensive patients with left ventricular hypertrophy

270 is measure of myocardial end-organ damage in hypertensive patients with LV hypertrophy.

271 By contrast, hypertensive patients with LVH (group 2), had significan

272 ventricular hypertrophy (LVH) (n = 80), and hypertensive patients with LVH on resting electrocardiog

273 Finally, in 39 hypertensive patients with LVH, conduit and resistance a

274 divided into three groups: group 1: n = 13, hypertensive patients with LVH; group 2: n = 30, hyperte

275 uction (LIFE) echocardiography substudy, 939 hypertensive patients with measurable LVM at baseline we

276 We randomly assigned 1715 hypertensive patients with nephropathy due to type 2 dia

277 Some studies suggest that 10%-40% of elderly hypertensive patients with newly documented ESRD and no

278 We conclude that in hypertensive patients with nifedipine-induced GH, switch

279 e mortality or cardiovascular events because hypertensive patients with normal LVM seem to be a low-r

280 culating biomarkers of heart failure (HF) in hypertensive patients with normal resting echocardiograp

281 up A) and 4 control groups: obese, diabetic, hypertensive patients with normal vitamin D (group B; n=

282 Greece, Ireland, Japan, the UK, and the USA, hypertensive patients with office systolic blood pressur

283 e three annual time points (Year 1, 2 and 3) hypertensive patients with proteinuria had the worst gra

284 on of the WNK1 gene were found in a group of hypertensive patients with pseudohypoaldosteronism type

285 Hypertensive patients with relatively mild LVH without e

286 ive, double-blinded, randomized study of 291 hypertensive patients with symptomatic paroxysmal AF who

287 Data from 1590 hypertensive patients with type 2 diabetes in the Irbesa

288 btained macrophages from 76 obese, diabetic, hypertensive patients with vitamin D deficiency (25-hydr

289 tamin D (group B; n=15); obese, nondiabetic, hypertensive patients with vitamin D deficiency (group C

290 istance coronary vasomotor responsiveness in hypertensive patients without atherosclerosis.

291 In hypertensive patients without clinically evident vascula

292 to the risk of primary cardiac arrest among hypertensive patients without clinically recognized hear

293 s with disc hemorrhages compared with ocular hypertensive patients without disc hemorrhages.

294 grouped into normotensive patients (n = 98), hypertensive patients without left ventricular hypertrop

295 In 28 hypertensive patients without left ventricular hypertrop

296 h left ventricular hypertrophy (HTN LVH) and hypertensive patients without LVH (HTN non-LVH) using ca

297 Compared with hypertensive patients without LVH (n=191; 74.6%) and tho

298 By contrast, no hypertensive patients without LVH had an abnormally low

299 asurements between normotensive patients and hypertensive patients without LVH.

300 rtensive patients with LVH; group 2: n = 30, hypertensive patients without LVH; group 3: n = 68, norm